Best J D, Chan V, Khoo R, Teng C S, Wang C, Yeung R T
Clin Radiol. 1981 Jan;32(1):57-61. doi: 10.1016/s0009-9260(81)80253-x.
The incidence of hypothyroidism in 1396 Chinese patients in Hong Kong treated for hyperthyroidism with 131I therapy is presented using the life-table method of analysis. One year after therapy only 6% of patients were hypothyroid, but the subsequent annual incidence was 3.5%, emphasising the need for life-time surveillance of these patients. A higher incidence of subsequent hypothyroidism was found in patients with diffuse surgical treatment, the total dose or number of doses of 131I, the severity of thyrotoxicosis and the age of the patient did not influence the rate of onset of hypothyroidism. The data suggest that in order to minimise the occurrence of hypothyroidism a lower dose of 131I per gram of thyroid mass should be used for patients with small diffuse glands.
采用寿命表分析法，呈现了香港1396例接受¹³¹I治疗甲亢的中国患者甲状腺功能减退症的发病率。治疗一年后，只有6%的患者出现甲状腺功能减退，但随后的年发病率为3.5%，这凸显了对这些患者进行终身监测的必要性。在接受弥漫性手术治疗的患者中，随后发生甲状腺功能减退的发生率较高，¹³¹I的总剂量或剂量数、甲状腺毒症的严重程度以及患者年龄均不影响甲状腺功能减退症的发病速率。数据表明，为了尽量减少甲状腺功能减退症的发生，对于弥漫性小腺体患者，每克甲状腺组织应使用较低剂量的¹³¹I。
